Uncovering subclinical cardiotoxicity across chemotherapy phases in pediatric oncology
Although the overall incidence of overt ventricular dysfunction was low, the use of ECG and GLS enhanced the sensitivity for detecting of subclinical cardiac impairment in pediatric patients receiving chemotherapy.
Authors
- Maite Gorostegui (ORCID: https://orcid.org/0000-0003-1393-9300)
- Maria C. Escobar‐Diaz (ORCID: https://orcid.org/0000-0001-9875-3593)
- Andrés Morales La Madrid (ORCID: https://orcid.org/0000-0001-7083-4316)
- Paula C. Randanne (ORCID: https://orcid.org/0000-0003-2129-7889)
- Cristina Rivera
- Esther Aurensanz Clemente (ORCID: https://orcid.org/0000-0002-1521-9553)
- Patricia García‐Canadilla (ORCID: https://orcid.org/0000-0002-0223-1617)
- Joan Sanchez-de-Toledo
Institutions
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Pittsburgh (US)
- Sant Joan de Déu Research Foundation (ES)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.3389/fonc.2025.1623081
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sociedad Española de Cardiología
- Ministerio de Ciencia, Innovación y Universidades
- European Commission
- Agencia Estatal de Investigación